Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28509133
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Denosumab for treatment of immobilization-related hypercalcemia in a patient with
end-stage renal disease
#MMPMID28509133
Uehara A
; Yazawa M
; Kawata A
; Hachisuka R
; Shibagaki Y
CEN Case Rep
2017[May]; 6
(1
): 111-114
PMID28509133
show ga
The efficacy and safety of denosumab for the treatment of immobilization-related
hypercalcemia in end-stage renal disease remain uncertain. We describe the case
of a hemodialysis patient with immobilization-related hypercalcemia who was
successfully treated with denosumab. A 79-year-old man admitted for hemodialysis
after sustaining an acute kidney injury developed immobilization-related
hypercalcemia due to the impairment resulting from an acute myocardial
infarction, acute heart failure, and catheter-related bloodstream infection.
After admission, the patient's corrected serum calcium rose to 12.9 from
8.8 mg/dL. A bisphosphonate (alendronate) was administered, but it was
ineffective. Subsequently, treatment with denosumab proved to be effective and
his corrected serum calcium level declined to 9.3 mg/dL within 1 week.
Hypocalcemia, which is an adverse effect of denosumab, was prevented using active
vitamin D and calcium supplementation, and his calcium level stabilized. Thus,
our case demonstrates that denosumab is a viable therapeutic option for dialysis
patients experiencing immobilization-related hypercalcemia.
free
free
free
